Although phosphorylated tau isoform 217 (p‐tau217) has recently emerged as the most promising biomarker for AD diagnosis due to its higher specificity and sensitivity, plasma p‐tau181 remains a valuable and widely studied marker, identifying individuals at risk of developing AD dementia even when clinical symptoms are not yet so prominent [9, 10]. Here, MAPT is linked to Alzheimer disease.